Post-infarction scarring irreversibly drives ischemic heart failure. Cardioselective lipid nanoparticles delivering anti-FAP mRNA transiently reprogram circulating T cells in vivo, producing a 38% fib…
❤️ Transient In Vivo Reprogramming: Circulating T-lymphocytes express anti-FAP receptors for 72 hours, dissolving 38% of post-infarction scar collagen.
📈 Hemodynamic Recovery: Left ventricular ejection fraction improved by +16% without triggering secondary arrhythmogenic foci.
Therapeutic Modality: In vivo transient mRNA CAR-T
Fibrosis Regression: 38% volume reduction
Ejection Fraction: +16% boost
Post-infarction scarring irreversibly drives ischemic heart failure. Cardioselective lipid nanoparticles delivering anti-FAP mRNA transiently reprogram circulating T cells in vivo, producing a 38% fibrosis reduction and a 16% ejection fraction improvement.
Eliminates ex vivo cell harvesting and processing, enabling off-the-shelf anti-fibrotic infusion regimens.
Regulatory frameworks and infrastructure readiness remain critical.
In vivo mRNA immunotherapies will prevent up to 60% of end-stage heart transplants by 2030.